Scholarlink

<p>Immune checkpoint inhibitors (ICIs) are a key component of first-line treatment for metastatic renal cell carcinoma (mRCC). However, predicting treatment-related adverse events (TRAEs) remains challenging. This study investigated the utility of eosinophil-related biomarkers as predictors of Common Terminology Criteria for Adverse Events grade ≥ 3 TRAEs in mRCC patients undergoing ICI combination therapy. In this retrospective analysis across 21 hospitals in Japan, we examined 180 patients treated with ICI/ICI therapy and 216 patients treated with ICI/tyrosine kinase inhibitor (TKI) therapy. Grade ≥ 3 TRAEs occurred in 39.4% and 31.9% of patients in the ICI/ICI and ICI/TKI groups, respectively. An elevated eosinophil proportion of ≥ 2.0% (odds ratio [OR]: 2.36; 95% CI [confidence interval] 1.23–4.54, p = 0.01) and a low neutrophil/eosinophil ratio (NER) of ≤ 40.0 (OR: 2.78, 95% CI 1.39–5.53, p = 0.004) were significant predictors of severe TRAEs in the ICI/ICI group. However, no significant associations were found in the ICI/TKI group. These findings may help identify patients who suffer from grade ≥ 3 TRAEs and help determine individualized treatment strategies in patients with mRCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月25日

查看全文
  • Tatsushi Kawada,
  • Satoshi Katayama,
  • Takafumi Yanagisawa,
  • Keiichiro Mori,
  • Wataru Fukuokaya,
  • Kazumasa Komura,
  • Takuya Tsujino,
  • Ryoichi Maenosono,
  • Kiyoshi Takahara,
  • Takuhisa Nukaya,
  • Lan Inoki,
  • Shingo Toyoda,
  • Takeshi Hashimoto,
  • Yosuke Hirasawa,
  • Kohei Edamura,
  • Tomoko Kobayashi,
  • Kensuke Bekku,
  • Shingo Nishimura,
  • Takehiro Iwata,
  • Takuya Sadahira,
  • Yusuke Tominaga,
  • Tomoaki Yamanoi,
  • Kasumi Yoshinaga,
  • Kazuma Tsuboi,
  • Yasuyuki Kobayashi,
  • Atsushi Takamoto,
  • Kyohei Kurose,
  • Takahiro Kimura,
  • Haruhito Azuma,
  • Ryoichi Shiroki,
  • Kazutoshi Fujita,
  • Yoshio Ohno,
  • Motoo Araki

摘要

Immune checkpoint inhibitors (ICIs) are a key component of first-line treatment for metastatic renal cell carcinoma (mRCC). However, predicting treatment-related adverse events (TRAEs) remains challenging. This study investigated the utility of eosinophil-related biomarkers as predictors of Common Terminology Criteria for Adverse Events grade ≥ 3 TRAEs in mRCC patients undergoing ICI combination therapy. In this retrospective analysis across 21 hospitals in Japan, we examined 180 patients treated with ICI/ICI therapy and 216 patients treated with ICI/tyrosine kinase inhibitor (TKI) therapy. Grade ≥ 3 TRAEs occurred in 39.4% and 31.9% of patients in the ICI/ICI and ICI/TKI groups, respectively. An elevated eosinophil proportion of ≥ 2.0% (odds ratio [OR]: 2.36; 95% CI [confidence interval] 1.23–4.54, p = 0.01) and a low neutrophil/eosinophil ratio (NER) of ≤ 40.0 (OR: 2.78, 95% CI 1.39–5.53, p = 0.004) were significant predictors of severe TRAEs in the ICI/ICI group. However, no significant associations were found in the ICI/TKI group. These findings may help identify patients who suffer from grade ≥ 3 TRAEs and help determine individualized treatment strategies in patients with mRCC.